TSUBAKI Masanobu 椿正寛

… Alternative Names

椿正寛ツバキマサノブ

Less

Researcher Number	30434856
Other IDs
Affiliation (Current)	2023: 近畿大学, 薬学部, 准教授
Affiliation (based on the past Project Information) *help	2020 – 2021: 近畿大学, 薬学部, 准教授 2017 – 2018: 近畿大学, 薬学部, 准教授 2013 – 2016: 近畿大学, 薬学部, 講師
Review Section/Research Field	Principal Investigator Basic Section 47060:Clinical pharmacy-related / Medical pharmacy / Pharmacology in pharmacy Except Principal Investigator Medical pharmacy
Keywords	Principal Investigator 分子標的薬 / 末梢神経障害 / 抗がん剤誘発末梢神経障害 / がん化学療法 / オキサリプラチン / パクリタキセル / シグナル伝達因子 / ERK / PKC / 抑制薬 … More Except Principal Investigator … More イマチニブ耐性 / BCR-ABL阻害薬 / イマチニブ / 慢性骨髄性白血病 / CAM-DR / 多発性骨髄腫 / 分子標的薬 / 抗癌剤耐性 Less

がん化学療法誘発末梢神経障害の機序解明と新規治療法の開発Principal Investigator
- Principal Investigator
  
  椿正寛
- Project Period (FY)
  2020 – 2022
- Research Category
  
  Grant-in-Aid for Scientific Research (C)
- Review Section
  
  Basic Section 47060:Clinical pharmacy-related
- Research Institution
  Kindai University
Application of molecular-targeted drugs for treatment of chemotherapy-induced peripheral neuropathyPrincipal Investigator
- Principal Investigator
  
  TSUBAKI Masanobu
- Project Period (FY)
  2016 – 2018
- Research Category
  
  Grant-in-Aid for Young Scientists (B)
- Research Field
  
  Medical pharmacy
- Research Institution
  Kindai University
Identification of imatinib resistance factor and the therapeutic strategies to overcome resistance in chronic myeloid leukemia
- Principal Investigator
  
  NISHIDA Shozo
- Project Period (FY)
  2015 – 2017
- Research Category
  
  Grant-in-Aid for Scientific Research (C)
- Research Field
  
  Medical pharmacy
- Research Institution
  Kindai University
Therapeutic strategy for oxaliplatin-induced neuropathy by mulecular targeting drugsPrincipal Investigator
- Principal Investigator
  
  TSUBAKI Masanobu
- Project Period (FY)
  2013 – 2015
- Research Category
  
  Grant-in-Aid for Young Scientists (B)
- Research Field
  
  Pharmacology in pharmacy
- Research Institution
  Kinki University
Investigation for the mechanism of anti-cancer drugs resistance and therapeutic strategy in multiple myeloma
- Principal Investigator
  
  NISHIDA Shozo
- Project Period (FY)
  2012 – 2014
- Research Category
  
  Grant-in-Aid for Scientific Research (C)
- Research Field
  
  Medical pharmacy
- Research Institution
  Kinki University

All 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 Other

All Journal Article Presentation

[Journal Article] Activation of Serum/Glucocorticoid Regulated Kinase 1/Nuclear Factor-κB Pathway Are Correlated with Low Sensitivity to Bortezomib and Ixazomib in Resistant Multiple Myeloma Cells2021
- Author(s)
  Tsubaki M, Takeda T, Matsuda T, Seki S, Tomonari Y, Koizumi S, Nagatakiya M, Katsuyama M, Yamamoto Y, Tsurushima K, Ishizaka T, Nishida S.
- Journal Title
  
  Biomedicines
  
  Volume: 9 Issue: 1 Pages: 33-33
- DOI
  10.3390/biomedicines9010033
- Peer Reviewed / Open Access
- Data Source
  KAKENHI-PROJECT-20K07145, KAKENHI-PROJECT-20K07168
[Journal Article] Perifosine enhances the potential antitumor effect of 5-fluorourasil and oxaliplatin in colon cancer cells harboring the PIK3CA mutation2021
- Author(s)
  Morii Y, Tsubaki M, Takeda T, Otubo R, Seki S, Yamatomo Y, Imano M, Satou T, Shimomura K, Nishida S.
- Journal Title
  
  Eur J Pharmacol.
  
  Volume: 898 Pages: 173957-173957
- DOI
  10.1016/j.ejphar.2021.173957
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-20K07145, KAKENHI-PROJECT-20K07168
[Journal Article] Gabapentin and Duloxetine Prevent Oxaliplatin- and Paclitaxel-Induced Peripheral Neuropathy by Inhibiting Extracellular Signal-Regulated Kinase 1/2 (ERK1/2) Phosphorylation in Spinal Cords of Mice2021
- Author(s)
  Kato N, Tateishi K, Tsubaki M, Takeda T, Matsumoto M, Tsurushima K, Ishizaka T, Nishida S.
- Journal Title
  
  Pharmaceuticals (Basel).
  
  Volume: 14 Issue: 1 Pages: 30-30
- DOI
  10.3390/ph14010030
- Peer Reviewed / Open Access
- Data Source
  KAKENHI-PROJECT-20K07145, KAKENHI-PROJECT-20K07168
[Journal Article] FTI-277 and GGTI-289 induce apoptosis via inhibition of the Ras/ERK and Ras/mTOR pathway in head and neck carcinoma HEp-2 and HSC-3 cells.2021
- Author(s)
  Tateishi K, Tsubaki M, Takeda T, Yamatomo Y, Imano M, Satou T, Nishida S.
- Journal Title
  
  J BUON
  
  Volume: 26 Pages: 606-612
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-20K07168
[Journal Article] Rhosin Suppressed Tumor Cell Metastasis through Inhibition of Rho/YAP Pathway and Expression of RHAMM and CXCR4 in Melanoma and Breast Cancer Cells2021
- Author(s)
  Tsubaki M, Genno S, Takeda T, Matsuda T, Kimura N, Yamashita Y, Morii Y, Shimomura K, Nishida S.
- Journal Title
  
  Biomedicines
  
  Volume: 9 Issue: 1 Pages: 35-35
- DOI
  10.3390/biomedicines9010035
- Peer Reviewed / Open Access
- Data Source
  KAKENHI-PROJECT-20K07145, KAKENHI-PROJECT-20K07168
[Journal Article] Interleukin 19 suppresses RANKL-induced osteoclastogenesis via the inhibition of NF-κB and p38MAPK activation and c-Fos expression in RAW264.7 cells.2021
- Author(s)
  Tsubaki M, Takeda T, Matsuda T, Yamamoto Y, Higashinaka A, Yamamoto K, Tsurushima K, Ishizaka T, Nishida S.
- Journal Title
  
  Cytokine
  
  Volume: 144 Pages: 155591-155591
- DOI
  10.1016/j.cyto.2021.155591
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-20K07145, KAKENHI-PROJECT-20K07168
[Journal Article] The HGF/Met/NF-κB Pathway Regulates RANKL Expression in Osteoblasts and Bone Marrow Stromal Cells2020
- Author(s)
  Tsubaki M, Seki S, Takeda T, Chihara A, Arai Y, Morii Y, Imano M, Satou T, Shimomura K, Nishida S.
- Journal Title
  
  Int J Mol Sci.
  
  Volume: 21 Issue: 21 Pages: 7905-7905
- DOI
  10.3390/ijms21217905
- Peer Reviewed / Open Access
- Data Source
  KAKENHI-PROJECT-20K07145, KAKENHI-PROJECT-20K07168
[Journal Article] Overexpression of HIF-1α contributes to melphalan resistance in multiple myeloma cells by activation of ERK1/2, Akt, and NF-κB.2019
- Author(s)
  Tsubaki M, Takeda T, Tomonari Y, Koumoto YI, Imano M, Satou T, Nishida S.
- Journal Title
  
  Lab Invest.
  
  Volume: 99 Issue: 1 Pages: 72-84
- DOI
  10.1038/s41374-018-0114-8
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-16K18965
[Journal Article] RANKL-induced c-Src activation contributes to conventional anti-cancer drug resistance and dasatinib overcomes this resistance in RANK-expressing multiple myeloma cells.2019
- Author(s)
  Mashimo K, Tsubaki M, Takeda T, Asano R, Jinushi M, Imano M, Satou T, Sakaguchi K, Nishida S.
- Journal Title
  
  Clin Exp Med.
  
  Volume: 19 Issue: 1 Pages: 133-141
- DOI
  10.1007/s10238-018-0531-4
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-16K18965
[Journal Article] Combination therapy with dacarbazine and statins improved the survival rate in mice with metastatic melanoma.2019
- Author(s)
  Tsubaki M, Takeda T, Obata N, Kawashima K, Tabata M, Imano M, Satou T, Nishida S.
- Journal Title
  
  J Cell Physiol.
  
  Volume: In press Issue: 10 Pages: 1-15
- DOI
  10.1002/jcp.28430
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-16K18965
[Journal Article] Trametinib suppresses chemotherapy-induced cold and mechanical allodynia via inhibition of extracellular-regulated protein kinase 1/2 activation.2018
- Author(s)
  Tsubaki M, Takeda T, Matsumoto M, Kato N, Asano RT, Imano M, Satou T, Nishida S.
- Journal Title
  
  Am J Cancer Res.
  
  Volume: 8 Pages: 1239-1248
- Peer Reviewed / Open Access
- Data Source
  KAKENHI-PROJECT-16K18965
[Journal Article] Tamoxifen suppresses paclitaxel-, vincristine-, and bortezomib-induced neuropathy via inhibition of the protein kinase C/extracellular signal-regulated kinase pathway.2018
- Author(s)
  Tsubaki M, Takeda T, Matsumoto M, Kato N, Yasuhara S, Koumoto YI, Imano M, Satou T, Nishida S.
- Journal Title
  
  Tumour Biol.
  
  Volume: 40 Issue: 10 Pages: 1-13
- DOI
  10.1177/1010428318808670
- Peer Reviewed / Open Access
- Data Source
  KAKENHI-PROJECT-16K18965
[Journal Article] The MIP-1α autocrine loop contributes to decreased sensitivity to anticancer drugs.2018
- Author(s)
  Tsubaki M, Takeda T, Tomonari Y, Mashimo K, Koumoto YI, Hoshida S, Itoh T, Imano M, Satou T, Sakaguchi K, Nishida S.
- Journal Title
  
  J Cell Physiol.
  
  Volume: 233 Issue: 5 Pages: 4258-4271
- DOI
  10.1002/jcp.26245
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-15K08116, KAKENHI-PROJECT-16K18965
[Journal Article] Bavachin induces the apoptosis of multiple myeloma cell lines by inhibiting the activation of nuclear factor kappa B and signal transducer and activator of transcription 3.2018
- Author(s)
  Takeda T, Tsubaki M, Tomonari Y, Kawashima K, Itoh T, Imano M, Satou T, Nishida Ｓ.
- Journal Title
  
  Biomed Pharmacother.
  
  Volume: 100 Pages: 486-494
- DOI
  10.1016/j.biopha.2018.02.019
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-17K15530, KAKENHI-PROJECT-15K08116
[Journal Article] Pioglitazone inhibits cancer cell growth through STAT3 inhibition and enhanced AIF expression via a PPARγ-independent pathway.2018
- Author(s)
  Tsubaki M, Takeda T, Tomonari Y, Kawashima K, Itoh T, Imano M, Satou T, Nishida S.
- Journal Title
  
  J Cell Physiol.
  
  Volume: 233 Issue: 4 Pages: 3638-3647
- DOI
  10.1002/jcp.26225
- Peer Reviewed / Open Access
- Data Source
  KAKENHI-PROJECT-15K08116, KAKENHI-PROJECT-17K01486, KAKENHI-PROJECT-16K18965
[Journal Article] Rebamipide suppresses 5-fluorouracil-induced cell death via the activation of Akt/mTOR pathway and regulates the expression of Bcl-2 family proteins.2018
- Author(s)
  Tsubaki M, Takeda T, Asano RT, Matsuda T, Fujimoto SI, Itoh T, Imano M, Satou T, Nishida S.
- Journal Title
  
  Toxicol In Vitro.
  
  Volume: 46 Pages: 284-293
- DOI
  10.1016/j.tiv.2017.10.019
- Peer Reviewed / Open Access
- Data Source
  KAKENHI-PROJECT-16K18965, KAKENHI-PROJECT-15K08116, KAKENHI-PROJECT-17K01486
[Journal Article] Contributions of MET activation to BCR-ABL1 tyrosine kinase inhibitor resistance in chronic myeloid leukemia cells.2017
- Author(s)
  Tsubaki M, Takeda T, Kino T, Sakai K, Itoh T, Imano M, Nakayama T, Nishio K, Satou T, Nishida S.
- Journal Title
  
  Oncotarget
  
  Volume: In press
- Peer Reviewed / Acknowledgement Compliant
- Data Source
  KAKENHI-PROJECT-15K08116
[Journal Article] Contributions of MET activation to BCR-ABL1 tyrosine kinase inhibitor resistance in chronic myeloid leukemia cells.2017
- Author(s)
  Tsubaki M, Takeda T, Kino T, Sakai K, Itoh T, Imano M, Nakayama T, Nishio K, Satou T, Nishida S.
- Journal Title
  
  Oncotarget.
  
  Volume: 8 Issue: 24 Pages: 38717-38730
- DOI
  10.18632/oncotarget.16314
- Peer Reviewed / Open Access
- Data Source
  KAKENHI-PROJECT-16K18965, KAKENHI-PROJECT-15K00898, KAKENHI-PROJECT-15K08116
[Journal Article] Statins induce apoptosis through inhibition of Ras signaling pathways and enhancement of Bim and p27 expression in human hematopoietic tumor cells.2017
- Author(s)
  Fujiwara D, Tsubaki M, Takeda T, Tomonari Y, Koumoto YI, Sakaguchi K, Nishida S.
- Journal Title
  
  Tumour Biol.
  
  Volume: 39 Pages: 1-11
- Peer Reviewed / Open Access
- Data Source
  KAKENHI-PROJECT-16K18965
[Journal Article] The sensitivity of head and neck carcinoma cells to statins is related to the expression of their Ras expression status, and statin-induced apoptosis is mediated via suppression of the Ras/ERK and Ras/mTOR pathways.2017
- Author(s)
  Tsubaki M, Fujiwara D, Takeda T, Kino T, Tomonari Y, Itoh T, Imano M, Satou T, Sakaguchi K, Nishida S.
- Journal Title
  
  Clin Exp Pharmacol Physiol.
  
  Volume: 44 Issue: 2 Pages: 222-234
- DOI
  10.1111/1440-1681.12690
- Peer Reviewed / Acknowledgement Compliant
- Data Source
  KAKENHI-PROJECT-15K08116, KAKENHI-PROJECT-15K00898
[Journal Article] Statins induce apoptosis through inhibition of Ras signaling pathways and enhancement of Bim and p27 expression in human hematopoietic tumor cells.2017
- Author(s)
  Fujiwara D, Tsubaki M, Takeda T, Tomonari Y, Koumoto YI, Sakaguchi K, Nishida S.
- Journal Title
  
  Tumour Biol.
  
  Volume: 39 Pages: 0-11
- Peer Reviewed / Open Access
- Data Source
  KAKENHI-PROJECT-15K08116
[Journal Article] Mangiferin induces apoptosis in multiple myeloma cell lines by suppressing the activation of nuclear factor kappa B-inducing kinase.2016
- Author(s)
  Takeda T, Tsubaki M, Kino T, Yamagishi M, Iida M, Itoh T, Imano M, Tanabe G, Muraoka O, Satou T, Nishida S.
- Journal Title
  
  Chem Biol Interact.
  
  Volume: 251 Pages: 26-33
- DOI
  10.1016/j.cbi.2016.03.018
- Peer Reviewed / Acknowledgement Compliant
- Data Source
  KAKENHI-PROJECT-15K08116, KAKENHI-PROJECT-16K08313
[Journal Article] Mangiferin enhances the sensitivity of human multiple myeloma cells to anticancer drugs through suppression of the nuclear factor κB pathway2016
- Author(s)
  Takeda T, Tsubaki M, Kino T, Kawamura A, Isoyama S, Itoh T, Imano M, Tanabe G, Muraoka O, Satou T, Nishida S
- Journal Title
  
  Int J Oncol
  
  Volume: 48 Issue: 6 Pages: 303-309
- DOI
  10.3892/ijo.2016.3470
- Peer Reviewed / Open Access
- Data Source
  KAKENHI-PROJECT-26350597, KAKENHI-PROJECT-15K00898, KAKENHI-PROJECT-15K08116, KAKENHI-PROJECT-16K08313
[Journal Article] RANK-RANKL interactions are involved in cell adhesion-mediated drug resistance in multiple myeloma cell lines.2016
- Author(s)
  Tsubaki M, Takeda T, Yoshizumi M, Ueda E, Itoh T, Imano M, Satou T, Nishida S.
- Journal Title
  
  Tumour Biol.
  
  Volume: 37 Issue: 7 Pages: 9099-9110
- DOI
  10.1007/s13277-015-4761-8
- Peer Reviewed / Acknowledgement Compliant
- Data Source
  KAKENHI-PROJECT-15K08116
[Journal Article] Statins inhibited the MIP-1α expression via inhibition of Ras/ERK and Ras/Akt pathways in myeloma cells.2016
- Author(s)
  Tsubaki M, Mashimo K, Takeda T, Kino T, Fujita A, Itoh T, Imano M, Sakaguchi K, Satou T, Nishida S.
- Journal Title
  
  Biomed Pharmacother.
  
  Volume: 78 Pages: 23-29
- DOI
  10.1016/j.biopha.2015.12.017
- Peer Reviewed / Acknowledgement Compliant / Int'l Joint Research
- Data Source
  KAKENHI-PROJECT-15K08116, KAKENHI-PROJECT-26350597, KAKENHI-PROJECT-15K00898
[Journal Article] RANK-RANKL interactions are involved in cell adhesion-mediated drug resistance in multiple myeloma cell lines.2016
- Author(s)
  Tsubaki M, Takeda T, Yoshizumi M, Ueda E, Itoh T, Imano M, Satou T, Nishida S.
- Journal Title
  
  Tumour Biol.
  
  Volume: in press
- Peer Reviewed / Acknowledgement Compliant
- Data Source
  KAKENHI-PROJECT-25860071
[Journal Article] Mangiferin, a novel nuclear factor kappa B-inducing kinase inhibitor, suppresses metastasis and tumor growth in a mouse metastatic melanoma model.2016
- Author(s)
  Takeda T, Tsubaki M, Sakamoto K, Ichimura E, Enomoto A, Suzuki Y, Itoh T, Imano M, Tanabe G, Muraoka O, Matsuda H, Satou T, Nishida S.
- Journal Title
  
  Toxicol Appl Pharmacol.
  
  Volume: 306 Pages: 105-112
- DOI
  10.1016/j.taap.2016.07.005
- Peer Reviewed / Acknowledgement Compliant
- Data Source
  KAKENHI-PROJECT-15K08116, KAKENHI-PROJECT-16K08313
[Journal Article] Statins improve survival by inhibiting spontaneous metastasis and tumor growth in a mouse melanoma model.2015
- Author(s)
  Tsubaki M, Takeda T, Kino T, Obata N, Itoh T, Imano M, Mashimo K, Fujiwara D, Sakaguchi K, Satou T, Nishida S.
- Journal Title
  
  Am J Cancer Res.
  
  Volume: 5 Pages: 3186-3197
- Peer Reviewed / Acknowledgement Compliant / Open Access
- Data Source
  KAKENHI-PROJECT-25860071
[Journal Article] Bisphosphonates and statins inhibit expression and secretion of MIP-1α via suppression of Ras/MEK/ERK/AML-1A and Ras/PI3K/Akt/AML-1A pathways.2015
- Author(s)
  Tsubaki M, Takeda T, Sakamoto K, Shimaoka H, Fujita A, Itoh T, Imano M, Mashimo K, Fujiwara D, Sakaguchi K, Satou T, Nishida S.
- Journal Title
  
  Am J Cancer Res.
  
  Volume: 5 Pages: 168-79
- Data Source
  KAKENHI-PROJECT-24590224
[Journal Article] Statins improve survival by inhibiting spontaneous metastasis and tumor growth in a mouse melanoma model.2015
- Author(s)
  Tsubaki M, Takeda T, Kino T, Obata N, Itoh T, Imano M, Mashimo K, Fujiwara D, Sakaguchi K, Satou T, Nishida S.
- Journal Title
  
  Am J Cancer Res.
  
  Volume: 5 Pages: 3186-3197
- Peer Reviewed / Acknowledgement Compliant / Open Access
- Data Source
  KAKENHI-PROJECT-15K08116
[Journal Article] PKC/MEK inhibitors suppress oxaliplatin-induced neuropathy and potentiate the antitumor effects.2015
- Author(s)
  Tsubaki M, Takeda T, Tani T, Shimaoka H, Suzuyama N, Sakamoto K, Fujita A, Ogawa N, Itoh T, Imano M, Funakami Y, Ichida S, Satou T, Nishida S.
- Journal Title
  
  Int J Cancer.
  
  Volume: In press Issue: 1 Pages: 243-250
- DOI
  10.1002/ijc.29367
- Peer Reviewed / Acknowledgement Compliant
- Data Source
  KAKENHI-PROJECT-24590224, KAKENHI-PROJECT-25860071
[Journal Article] Overexpression of survivin via activation of ERK1/2, Akt, and NF-κB plays a central role in vincristine resistance in multiple myeloma cells.2015
- Author(s)
  Tsubaki M, Takeda T, Ogawa N, Sakamoto K, Shimaoka H, Fujita A, Itoh T, Imano M, Ishizaka T, Satou T, Nishida S.
- Journal Title
  
  Leuk Res.
  
  Volume: 39 Issue: 4 Pages: 445-52
- DOI
  10.1016/j.leukres.2015.01.016
- Peer Reviewed / Acknowledgement Compliant
- Data Source
  KAKENHI-PROJECT-24590224, KAKENHI-PROJECT-15K08116
[Journal Article] Mangiferin suppresses CIA by suppressing the expression of TNF-α, IL-6, IL-1β, and RANKL through inhibiting the activation of NF-κB and ERK1/2.2015
- Author(s)
  Tsubaki M, Takeda T, Kino T, Itoh T, Imano M, Tanabe G, Muraoka O, Satou T, Nishida S.
- Journal Title
  
  Am J Transl Res.
  
  Volume: 7 Pages: 1371-1381
- Peer Reviewed / Acknowledgement Compliant / Open Access
- Data Source
  KAKENHI-PROJECT-25860071
[Journal Article] By inhibiting Src, verapamil and dasatinib overcome multidrug resistance via increased expression of Bim and decreased expressions of MDR1 and survivin in human multidrug-resistant myeloma cells.2014
- Author(s)
  Tsubaki M, Komai M, Itoh T, Imano M, Sakamoto K, Shimaoka H, Takeda T, Ogawa N, Mashimo K, Fujiwara D, Mukai J, Sakaguchi K, Satou T, Nishida S
- Journal Title
  
  Leuk Res
  
  Volume: 38 Issue: 1 Pages: 120-130
- DOI
  10.1016/j.leukres.2013.10.017
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-24501009, KAKENHI-PROJECT-24590224
[Journal Article] Nitrogen-containing bisphosphonates inhibit RANKL- and M-CSF-induced osteoclast formation through the inhibition of ERK1/2 and Akt activation.2014
- Author(s)
  Tsubaki M, Komai M, Itoh T, Imano M, Sakamoto K, Shimaoka H, Takeda T, Ogawa N, Mashimo K, Fujiwara D, Mukai J, Sakaguchi K, Satou T, Nishida S.
- Journal Title
  
  J Biomed Sci.
  
  Volume: 21 Issue: 1 Pages: 10-10
- DOI
  10.1186/1423-0127-21-10
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-24590224, KAKENHI-PROJECT-26350597
[Journal Article] Dimethyl fumarate induces apoptosis of hematopoietic tumor cells via inhibition of NF-κB nuclear translocation and down-regulation of Bcl-xL and XIAP.2014
- Author(s)
  Tsubaki M, Ogawa N, Takeda T, Sakamoto K, Shimaoka H, Fujita A, Itoh T, Imano M, Satou T, Nishida S.
- Journal Title
  
  Biomed Pharmacother.
  
  Volume: 68 Issue: 8 Pages: 999-1005
- DOI
  10.1016/j.biopha.2014.09.009
- Peer Reviewed / Acknowledgement Compliant
- Data Source
  KAKENHI-PROJECT-24590224
[Journal Article] Inhibition of the tumour necrosis factor-alpha autocrine loop enhances the sensitivity of multiple myeloma cells to anticancer drugs.2013
- Author(s)
  Tsubaki M, Komai M, Itoh T, Imano M, Sakamoto K, Shimaoka H, Ogawa N, Mashimo K, Fujiwara D, Takeda T, Mukai J, Sakaguchi K, Satou T, Nishida S.
- Journal Title
  
  Eur J Cancer.
  
  Volume: 47 Issue: 17 Pages: 3708-17
- DOI
  10.1016/j.ejca.2013.07.010
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-24590224
[Journal Article] Overexpression of MDR1 and survivin, and decreased Bim expression mediate multidrug-resistance in multiple myeloma cells.2012
- Author(s)
  Tsubaki M, Satou T, Itoh T, Imano M, Komai M, Nishinobo M, Yamashita M, Yanae M, Yamazoe Y, Nishida S.
- Journal Title
  
  Leuk Res.
  
  Volume: 36 Issue: 10 Pages: 1315-1322
- DOI
  10.1016/j.leukres.2012.07.003
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-24590224
[Presentation] Akt 阻害剤は PIK3CA 変異大腸癌においてオキサリプラチン及び 5-フルオロウラシルの感受性を増大させる2021
- Author(s)
  森井悠介、椿正寛、武田朋也、松田拓弥、山本裕太、岸本佳奈、西田升三
- Organizer
  第25回日本がん分子標的治療学会学術集会
- Data Source
  KAKENHI-PROJECT-20K07168
[Presentation] Akt inhibitor enhances the sensitivity to oxaliplatin and 5-fluorourasil in PIK3CA-mutated colon cancer2021
- Author(s)
  Shozo Nishida, Masanobu Tsubaki, Tomoya Takeda, TakuyaMatsuda, Yuuta Yamamoto, Kana Kishimoto
- Organizer
  The 80th Annual Meeting of the Japanese Cancer Association
- Data Source
  KAKENHI-PROJECT-20K07168
[Presentation] Perifosine enhances sensitivity of oxaliplatin and 5-fluorourasil in PIK3CA-mutated colorectal cancer.2020
- Author(s)
  Yuuta Yamamoto, Masanobu Tsubaki, Tomoya Takeda, Shiori Seki, Shozo Nishida.
- Organizer
  The 79th Annual Meeting of the Japanese Cancer Association
- Data Source
  KAKENHI-PROJECT-20K07168
[Presentation] Rhosin suppressed tumor metastasis by inhibition Rho/YAP pathway and expression of RHAMM and CXCR4.2020
- Author(s)
  Shuji Genno, Masanobu Tsubaki, Tomoya Takeda, Shozo Nishida.
- Organizer
  The 79th Annual Meeting of the Japanese Cancer Association
- Data Source
  KAKENHI-PROJECT-20K07168
[Presentation] 新規NF-kappaB/STAT3 阻害剤による多発性骨髄腫でのアポトーシス誘導機構の解析.2018
- Author(s)
  小泉翔太郎, 椿正寛, 武田朋也, 浅野良太, 川島啓司, 西田升三.
- Organizer
  日本薬学会第138回年会
- Data Source
  KAKENHI-PROJECT-15K08116
[Presentation] PKC阻害剤による抗がん剤誘導末梢神経障害抑制効果2018
- Author(s)
  加藤菜月、椿正寛、武田朋也、川島啓司、地主みなみ、藤本伸一郎、森井悠介、西田升三.
- Organizer
  第68回日本薬学会近畿支部総会・大会
- Data Source
  KAKENHI-PROJECT-16K18965
[Presentation] 多発性骨髄腫でのMIP-1alphaオートクラインは抗がん剤の感受性を低下させ抗がん剤耐性に寄与する.2017
- Author(s)
  河本雄一, 椿正寛, 武田朋也, 友成佳加, 浅野良太, 川島啓司, 眞下恵次, 阪口勝彦, 西田升三.
- Organizer
  第21回日本がん分子標的治療学会学術集会
- Data Source
  KAKENHI-PROJECT-15K08116
[Presentation] MET/ERK and MET/JNK pathways is involved with imatinibresistance in chronic myeloid leukemia.2017
- Author(s)
  Masanobu Tsubaki, Tomoya Takeda, Yu-ichi Koumoto, Shin-ichiro Fujimoto, Shozo Nishida.
- Organizer
  第76回日本癌学会学術総会
- Data Source
  KAKENHI-PROJECT-15K08116
[Presentation] PioglitazoneはSTAT3阻害を介してSurvivinの発現低下及びAIFの発現増加によりアポトーシスを誘導する.2017
- Author(s)
  浅野良太, 椿正寛, 武田朋也, 友成佳加, 藤原大一朗, 阪口勝彦, 西田升三.
- Organizer
  第21回日本がん分子標的治療学会学術集会
- Data Source
  KAKENHI-PROJECT-15K08116
[Presentation] Statins によるRas/ERK 及びRas/mTOR 経路阻害を介した造血器系腫瘍でのアポトーシス誘導機序.2017
- Author(s)
  伊藤麻祐, 椿正寛, 武田朋也, 友成佳加, 西田升三.
- Organizer
  第67回日本薬学会近畿支部総会・大会
- Data Source
  KAKENHI-PROJECT-15K08116
[Presentation] オキサリプラチン誘発末梢神経障害はPKC/MEK阻害剤で抑制できる2016
- Author(s)
  松本幹広、椿正寛、武田朋也、木野稔己、友成佳加、西田升三.
- Organizer
  第66回日本薬学会近畿支部総会・大会
- Place of Presentation
  大阪薬科大学（大阪府高槻市）
- Year and Date
  2016-10-15
- Data Source
  KAKENHI-PROJECT-16K18965
[Presentation] 慢性骨髄性白血病におけるイマチニブ耐性にMET活性化が関与する2016
- Author(s)
  椿正寛、武田朋也、木野稔己、友成佳加、眞下恵次、藤原大一朗、藤本伸一郎、阪口勝彦、山添譲、西田升三.
- Organizer
  第20回日本がん分子標的治療学会
- Place of Presentation
  別府国際コンベンションセンター（大分県別府市）
- Year and Date
  2016-05-31
- Data Source
  KAKENHI-PROJECT-15K08116
[Presentation] PKC及びMEK阻害剤によるオキサリプラチン誘発末梢神経障害の抑制及び抗腫瘍効果の増強.2016
- Author(s)
  椿正寛、武田朋也、木野稔己、藤原大一朗、山添譲、阪口勝彦、西田升三.
- Organizer
  日本薬学会第136回年会
- Place of Presentation
  パシフィコ横浜（神奈川県）
- Year and Date
  2016-03-27
- Data Source
  KAKENHI-PROJECT-25860071
[Presentation] MET activation is involved with imatinib-resistance in chronic myeloid leukemia.2016
- Author(s)
  椿正寛、武田朋也、木野稔己、友成佳加、藤本伸一郎、西田升三.
- Organizer
  第75回日本癌学会学術総会
- Place of Presentation
  パシフィコ横浜（神奈川県横浜市）
- Year and Date
  2016-10-07
- Data Source
  KAKENHI-PROJECT-15K08116
[Presentation] PKC 阻害剤はオキサリプラチン誘導末梢神経障害を抑制するとともに抗腫瘍効果を増強させる.2015
- Author(s)
  椿　正寛、武田　朋也、中橋　拓也、小川　直希、石坂　敏彦、西田　升三.
- Organizer
  第74回日本癌学会学術総会
- Place of Presentation
  名古屋国際会議場（愛知県）
- Year and Date
  2015-10-08
- Data Source
  KAKENHI-PROJECT-25860071
[Presentation] PKC 阻害剤はオキサリプラチン誘発末梢神経障害を抑制し抗腫瘍効果を増強させる.2015
- Author(s)
  安原　翔大、椿　正寛、武田　朋也、西田　升三.
- Organizer
  第65回日本薬学会近畿支部総会・大会
- Place of Presentation
  大阪大谷大学（大阪府）
- Year and Date
  2015-10-17
- Data Source
  KAKENHI-PROJECT-25860071
[Presentation] Bisphospohnates及びstatinsによる多発性骨髄腫でのMIP-1α分泌抑制効果2015
- Author(s)
  椿正寛、武田朋也、嶌岡弘高、坂本洸太郎、藤田亜里沙、小川直希、眞下恵次、藤原大一朗、山添譲、阪口勝彦、石坂敏彦、西田升三
- Organizer
  日本薬学会　第135年会
- Place of Presentation
  神戸（神戸学院大学）
- Year and Date
  2015-03-26
- Data Source
  KAKENHI-PROJECT-24590224
[Presentation] PKC/MEK阻害剤によりoxaliplatin誘導末梢神経障害を抑制できる.2015
- Author(s)
  椿　正寛、武田　朋也、藤田　亜梨沙、木野　稔己、中橋　拓也、小川　直希、山添　譲、石坂　敏彦、西田　升三.
- Organizer
  第19回日本がん分子標的治療学会
- Place of Presentation
  松山全日空ホテル（愛媛県）
- Year and Date
  2015-06-10
- Data Source
  KAKENHI-PROJECT-25860071
[Presentation] 造血器腫瘍でのインテグリンを介した抗がん剤耐性機序2014
- Author(s)
  上田　絵美、椿　正寛、武田　朋也、嶌岡　弘高、坂本　洸太郎、藤田　亜梨沙、西田　升三
- Organizer
  第64回日本薬学会近畿支部総会・大会
- Place of Presentation
  京都（京都薬科大学）
- Year and Date
  2014-10-11
- Data Source
  KAKENHI-PROJECT-24590224
[Presentation] Src 阻害に基づく抗がん剤耐性多発性骨髄腫での耐性克服効果2014
- Author(s)
  藤田　亜梨沙、椿　正寛、武田　朋也、嶌岡　弘高、坂本　洸太郎、小川　直希、山添　譲、向井　淳治、西田　升三.
- Organizer
  第73回日本癌学会学術総会
- Place of Presentation
  横浜（パシフィコ横浜）
- Year and Date
  2014-09-25
- Data Source
  KAKENHI-PROJECT-24590224
[Presentation] DMF によるNF-κB 阻害を介した造血器腫瘍でのアポトーシス誘導効果2014
- Author(s)
  橋口　りえ、椿　正寛、武田　朋也、嶌岡　弘高、坂本　洸太郎、藤田　亜梨沙、西田　升三
- Organizer
  第64回日本薬学会近畿支部総会・大会
- Place of Presentation
  京都（京都薬科大学）
- Year and Date
  2014-10-11
- Data Source
  KAKENHI-PROJECT-24590224
[Presentation] RANK/RANKLによるシグナル伝達因子活性化を介した多発性骨髄腫での抗がん剤耐性獲得機序.2014
- Author(s)
  椿　正寛、武田　朋也、嶌岡　弘高、坂本　洸太郎、藤田　亜里沙、眞下　恵次、藤原　大一郎、阪口　勝彦、西田　升三.
- Organizer
  第18回日本がん分子標的治療学会
- Place of Presentation
  宮城（仙台市情報・産業プラザ(AER) ホテルメトロポリタン仙台 TKPガーデンシティ仙台）
- Year and Date
  2014-06-27
- Data Source
  KAKENHI-PROJECT-24590224
[Presentation] 多発性骨髄腫での薬剤排泄トランスポーターとアポトーシス調節因子の発現調節を介した抗がん剤耐性機序の解明2014
- Author(s)
  椿　正寛、武田　朋也、嶌岡　弘高、坂本　洸太郎、藤田　亜梨沙、西田　升三
- Organizer
  第64回日本薬学会近畿支部総会・大会
- Place of Presentation
  京都（京都薬科大学）
- Year and Date
  2014-10-11
- Data Source
  KAKENHI-PROJECT-24590224
[Presentation] 多発性骨髄腫での抗がん剤多剤耐性獲得機序.2013
- Author(s)
  駒居真紀子、椿正寛、小川直希、山添譲、向井淳治、西田升三.
- Organizer
  日本薬学会第133年会
- Place of Presentation
  横浜
- Data Source
  KAKENHI-PROJECT-24590224
[Presentation] Overexpression of MDR1 and survivin, and decreased Bim expression mediate multidrug-resistance in multiple myeloma.2012
- Author(s)
  駒居真紀子、椿正寛、小川直希、山添譲、向井淳治、西田升三.
- Organizer
  第71回日本癌学会学術集会
- Place of Presentation
  札幌
- Data Source
  KAKENHI-PROJECT-24590224
[Presentation] MDR1及びsurvivinの過剰発現とBimの発現低下を介した多発性骨髄腫での多剤耐性獲得機序.2012
- Author(s)
  駒居真紀子、椿正寛、小川直希、山添譲、向井淳治、西田升三.
- Organizer
  第16回日本がん分子標的治療学会学術集会
- Place of Presentation
  小倉
- Data Source
  KAKENHI-PROJECT-24590224
[Presentation] シグナル伝達因子活性化による多発性骨髄腫での抗がん剤耐性獲得機序.
- Author(s)
  駒居　真紀子、椿　正寛、嶌岡　弘高、坂本　洸太郎、小川　直希、眞下　恵次、藤原　大一朗、山添　譲、阪口　勝彦、向井　淳治、西田　升三.
- Organizer
  第72回日本癌学会学術総会
- Place of Presentation
  パシフィコ横浜（神奈川県横浜市）
- Data Source
  KAKENHI-PROJECT-24590224
[Presentation] Src阻害を介した多発性骨髄腫での抗がん剤耐性克服機序.
- Author(s)
  小野　優里、椿　正寛、駒居　真紀子、嶌岡　弘高、坂本　洸太郎、小川　直希、眞下　恵次、藤原　大一朗、向井　淳治、阪口　勝彦、西田　升三.
- Organizer
  第63回日本薬学会近畿支部総会・大会
- Place of Presentation
  同志社女子大学京田辺キャンパス（京都府京田辺市）
- Data Source
  KAKENHI-PROJECT-24590224
[Presentation] TNF-alphaオートクライン阻害による抗がん剤殺細胞作用増強効果.
- Author(s)
  西田　升三、椿　正寛、駒居　真紀子、嶌岡　弘高、坂本　洸太郎、小川　直希、眞下　恵次、藤原　大一朗、山添　譲、阪口　勝彦、向井　淳治.
- Organizer
  第72回日本癌学会学術総会
- Place of Presentation
  パシフィコ横浜（神奈川県横浜市）
- Data Source
  KAKENHI-PROJECT-24590224
[Presentation] 多発性骨髄腫における多剤耐性獲得因子の検討.
- Author(s)
  駒居　真紀子、椿　正寛、嶌岡　弘高、坂本　洸太郎、小川　直希、眞下　恵次、藤原　大一朗、山添　譲、向井　淳治、阪口　勝彦、西田　升三.
- Organizer
  第60回日本生化学会近畿支部例会
- Place of Presentation
  大阪大学吹田キャンパス（大阪府吹田市）
- Data Source
  KAKENHI-PROJECT-24590224
[Presentation] RANK/RANKLによる多発性骨髄腫での抗がん剤耐性獲得機序.
- Author(s)
  椿　正寛、駒居　真紀子、嶌岡　弘高、坂本　洸太郎、小川　直希、眞下　恵次、藤原　大一朗、山添　譲、向井　淳治、西田　升三.
- Organizer
  第17回日本がん分子標的治療学会学術集会
- Place of Presentation
  国立京都国際会館（京都府京都市）
- Data Source
  KAKENHI-PROJECT-24590224

1. NISHIDA Shozo (40208187)

# of Collaborated Projects: 2 results

# of Collaborated Products: 44 results
2. TAKEDA Tomoya (20734031)

# of Collaborated Projects: 1 results

# of Collaborated Products: 18 results
3. ITOH Tatsuki

# of Collaborated Projects: 0 results

# of Collaborated Products: 2 results
4. SATOU Takao

# of Collaborated Projects: 0 results

# of Collaborated Products: 2 results

TSUBAKI Masanobu 椿 正寛

椿 正寛 ツバキ マサノブ

Research Projects

Research Products

Co-Researchers

がん化学療法誘発末梢神経障害の機序解明と新規治療法の開発Principal Investigator

Principal Investigator

Project Period (FY)

Research Category

Review Section

Research Institution

Application of molecular-targeted drugs for treatment of chemotherapy-induced peripheral neuropathyPrincipal Investigator

Principal Investigator

Project Period (FY)

Research Category

Research Field

Research Institution

Identification of imatinib resistance factor and the therapeutic strategies to overcome resistance in chronic myeloid leukemia

Principal Investigator

Project Period (FY)

Research Category

Research Field

Research Institution

Therapeutic strategy for oxaliplatin-induced neuropathy by mulecular targeting drugsPrincipal Investigator

Principal Investigator

Project Period (FY)

Research Category

Research Field

Research Institution

Investigation for the mechanism of anti-cancer drugs resistance and therapeutic strategy in multiple myeloma

Principal Investigator

Project Period (FY)

Research Category

Research Field

Research Institution

[Journal Article] Activation of Serum/Glucocorticoid Regulated Kinase 1/Nuclear Factor-κB Pathway Are Correlated with Low Sensitivity to Bortezomib and Ixazomib in Resistant Multiple Myeloma Cells2021

Author(s)

Journal Title

DOI

Data Source

[Journal Article] Perifosine enhances the potential antitumor effect of 5-fluorourasil and oxaliplatin in colon cancer cells harboring the PIK3CA mutation2021

Author(s)

Journal Title

DOI

Data Source

[Journal Article] Gabapentin and Duloxetine Prevent Oxaliplatin- and Paclitaxel-Induced Peripheral Neuropathy by Inhibiting Extracellular Signal-Regulated Kinase 1/2 (ERK1/2) Phosphorylation in Spinal Cords of Mice2021

Author(s)

Journal Title

DOI

Data Source

[Journal Article] FTI-277 and GGTI-289 induce apoptosis via inhibition of the Ras/ERK and Ras/mTOR pathway in head and neck carcinoma HEp-2 and HSC-3 cells.2021

Author(s)

Journal Title

Data Source

[Journal Article] Rhosin Suppressed Tumor Cell Metastasis through Inhibition of Rho/YAP Pathway and Expression of RHAMM and CXCR4 in Melanoma and Breast Cancer Cells2021

Author(s)

Journal Title

DOI

Data Source

[Journal Article] Interleukin 19 suppresses RANKL-induced osteoclastogenesis via the inhibition of NF-κB and p38MAPK activation and c-Fos expression in RAW264.7 cells.2021

Author(s)

Journal Title

DOI

Data Source

[Journal Article] The HGF/Met/NF-κB Pathway Regulates RANKL Expression in Osteoblasts and Bone Marrow Stromal Cells2020

Author(s)

Journal Title

DOI

Data Source

[Journal Article] Overexpression of HIF-1α contributes to melphalan resistance in multiple myeloma cells by activation of ERK1/2, Akt, and NF-κB.2019

Author(s)

Journal Title

DOI

Data Source

[Journal Article] RANKL-induced c-Src activation contributes to conventional anti-cancer drug resistance and dasatinib overcomes this resistance in RANK-expressing multiple myeloma cells.2019

Author(s)

Journal Title

DOI

Data Source

[Journal Article] Combination therapy with dacarbazine and statins improved the survival rate in mice with metastatic melanoma.2019

TSUBAKI Masanobu 椿正寛

椿正寛ツバキマサノブ